In the following video, Motley Fool health-care bureau chief Brenton Flynn takes a look at two different companies with drugs facing FDA approval decisions in February. He discusses ImmunoGen (IMGN) and its drug T-DM1, where approval is already expected by the market, as well as Dynavax (DVAX -2.19%) and its hepatitis B vaccine Heplisav. Dynavax is the wildcard of this group, and Brenton gives his prediction for whether or not the drug will be approved.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.